Tag: pharmaceuticals

A Natural Supplement Trend in 2025, Menovelle Helps Women Support Hormonal Balance and Metabolic Energy Without Hormone Therapy or Stimulants

Global medical cannabis market to hit USD 68.6 billion by 2033, growing at a 7.1% CAGR. Key growth drivers include increasing legalization and therapeutic use for conditions like chronic pain and epilepsy. North America leads due to progressive regulations. Top players like Canopy Growth and GW Pharmaceuticals drive innovation in the sector.

CONSHOHOCKEN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its second-quarter 2025 financial results on Wednesday, Aug. 5, 2025, prior to the open of the U.S. financial markets.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

The Europe Pyridine Market is set to grow from USD 198.85 million in 2024 to USD 288.21 million by 2033, at a CAGR of 4.21%. This growth is driven by rising demand in agrochemicals, pharmaceuticals, and food industries. Pyridine's versatility in solvents, pesticides, and chemical intermediates bolsters its usage in Europe. Key market drivers include sustainable agriculture and pharmaceutical expansion, particularly in France and Germany. However, challenges like stringent environmental regulations and volatile raw material prices persist. Leading players like Lonza Group and Bayer AG are pivotal in shaping the market.

SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company’s shares saw their investment crash over 60% that day.